Visão geral da empresa
A biotechnology enterprise operating within the healthcare sector, Gain Therapeutics, Inc. is dedicated to developing novel small molecule therapeutics designed to treat diseases across a variety of therapeutic areas in Switzerland, Spain, the United States, and Australia. The company utilizes a proprietary drug discovery platform named Magellan, which functions by discovering novel allosteric binding sites within diseases to advance its therapeutic pipeline. As of the latest reporting period, the entity operates with a market capitalization of $78.18M and employs a workforce of 20 individuals. These financial metrics indicate that Gain Therapeutics is a small-cap biotechnology firm with limited revenue generation, a characteristic common for early-stage companies focused on research and development rather than commercial sales. The market cap figure reflects the market's valuation of its future potential rather than current operational profitability, while the absence of reported annual revenue underscores its position as a pre-revenue or low-revenue entity typical of the biotechnology industry.
Saúde financeira
Gain Therapeutics reports a net income of $-20,161,100 and an EBITDA of $-18,685,844, while annual revenue is not available in the provided data. The substantial gap between the non-existent revenue and the significant negative net income reveals a cost structure entirely driven by high operating expenses associated with drug discovery and research activities rather than cost of goods sold. The company generates a free cash flow of $-10,501,040, which indicates a consumption of cash resources necessary to fund its ongoing operations and development efforts. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which signifies that the company has not yet achieved commercial scale or profitability from sales to offset its research expenditures. Regarding liquidity, the company holds $20.84M in cash against total debt of $732,067, resulting in a debt-to-equity ratio of 3.94. Despite the high leverage indicated by the debt-to-equity ratio, the balance sheet is supported by a significant cash reserve that far exceeds the debt obligations. The current ratio stands at 6.63, which suggests a robust short-term liquidity position where current assets significantly exceed current liabilities. Finally, the return on equity is -155.7% and the return on assets is -67.0%, metrics that reveal that management is currently unable to generate positive returns on the capital invested, a typical scenario for biotechnology firms in the discovery phase.
Avaliação de valorização
The trailing twelve-month P/E ratio is not available, while the forward P/E is listed at -2.95, implying that the market is pricing the stock based on future expectations of earnings that are currently negative or negligible. The price-to-book ratio is 4.17, indicating that the market values the company at a significant premium over its tangible book value, likely reflecting the intangible value of its intellectual property and pipeline potential. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are not available or are negative at -3.08, suggesting that traditional valuation multiples are not applicable due to the lack of positive earnings or sales data. The stock's price range over the last 52 weeks spans from a low of $1.41 to a high of $4.34. Without the specific current share price provided in the facts, the relative position cannot be calculated as a percentage, but the range demonstrates the volatility experienced by small-cap biotech stocks. The beta value is 0.11, which indicates that the stock exhibits low price volatility relative to the broader market, moving significantly less than the general market index. This low beta suggests that the stock price is less sensitive to general market fluctuations, often driven instead by specific developments in the company's therapeutic pipeline.
Growth & Income
The available data indicates that revenue growth year-over-year and earnings growth year-over-year are not available (N/A). Consequently, it is not possible to determine if earnings are growing faster or slower than revenue based on the provided figures. Gain Therapeutics does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company reinvests all available resources into research, development, and operational growth rather than distributing income to shareholders. The overall growth and income profile is characterized by a lack of historical earnings growth data and a complete absence of dividend income, positioning the company as a pure play on future drug development success rather than current income generation. The absence of dividend payments is standard for biotechnology companies that prioritize capital expenditure on clinical trials and regulatory approvals over shareholder distributions. Investors analyzing this profile must rely on the potential for value creation through successful drug approvals rather than traditional income metrics or consistent historical growth rates.